UK investors point to positives of Pfizer/ AstraZeneca deal

'Putting the two together in emerging markets would boost scale and credibility though that network', says Schroders' Sue Noffke

UK shareholders in AstraZeneca have pointed to the positives of a potential tie-up with US drugs giant Pfizer, a sign that could be of crucial significance in a so-far frosty bid process.

This morning Pfizer confirmed it had contacted AstraZeneca for a second time with regards to a potential acquisition, having first tabled a bid in January this year.

WSJ Logo
Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With TrumpExternal link

Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With Trump